Drug Shortage Report for TEVA-MOMETASONE
Report ID | 170764 |
Drug Identification Number | 02475863 |
Brand name | TEVA-MOMETASONE |
Common or Proper name | TEVA-MOMETASONE FURO SPRAY |
Company Name | TEVA CANADA LIMITED |
Market Status | MARKETED |
Active Ingredient(s) | MOMETASONE FUROATE |
Strength(s) | 50MCG |
Dosage form(s) | SPRAY, METERED DOSE |
Route of administration | NASAL NASAL |
Packaging size | 1 |
ATC code | R01AD |
ATC description | DECONGESTANTS AND OTHER NASAL PREP.FOR TOPICAL USE |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2022-09-30 |
Estimated end date | 2022-10-30 |
Actual end date | 2022-10-28 |
Shortage status | Resolved |
Updated date | 2022-10-29 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v6 | 2022-10-29 | English | Compare |
v5 | 2022-10-28 | French | Compare |
v4 | 2022-10-28 | English | Compare |
v3 | 2022-10-01 | English | Compare |
v2 | 2022-09-30 | French | Compare |
v1 | 2022-09-30 | English | Compare |
Showing 1 to 6 of 6